person · Reporting owner
Kroeger Christopher A.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 1,269,600 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 23,145 · Balance 1,269,600 F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.25 · Expires 2036-08-16 | Direct | 93,955 |
Reported balance
After 2026-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-17 · Grant · Acquired 93,955 · Balance 93,955 F4: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnote | 101,190 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 101,190 F3: The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3: The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
F4: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tempest Therapeutics, Inc.
Report date December 07, 2018 · Filed December 12, 2018
Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2028-05-10 | Direct | 47,666 |
Reported balance
After 2018-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-10 · Grant · Acquired 47,666 · Balance 47,666 F1: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F2: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.
F2: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 93,955 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0001658918-26-000016 · form4-08192026_060801.xml · derivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,955 Underlying: Voting Common Stock · 93,955 shares Expires 2036-08-16 F4 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 23,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001658918-26-000016 · form4-08192026_060801.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269,600 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| July 17, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 16,779 | $37.90 | $635,924.10 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 7 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246,455 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 92 | $37.96 | $3,492.32 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 6 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,263,234 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 28,091 | $37.26 | $1,046,670.66 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 5 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,263,326 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 40,899 | $36.46 | $1,491,177.54 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 4 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,291,417 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 90 | $37.54 | $3,378.60 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,332,316 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 42,738 | $36.99 | $1,580,878.62 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,332,406 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:46 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 18,950 | $36.00 | $682,200.00 |
DisclosureSEC source: 0001658918-26-000014 · form4-07182026_010744.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,375,144 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 18, 2026 Filed May 19, 2026 01:27 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 198 | $28.15 | $5,573.70 |
DisclosureSEC source: 0001658918-26-000012 · form4-05192026_010517.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,394,094 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.57 to $28.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 18, 2026 Filed May 19, 2026 01:27 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 118,037 | $27.19 | $3,209,426.03 |
DisclosureSEC source: 0001658918-26-000012 · form4-05192026_010517.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,394,292 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.565 to $27.4347 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,890 | $30.56 | $179,998.40 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 9 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,512,329 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 6,871 | $30.04 | $206,404.84 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 8 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,518,219 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 877 | $28.70 | $25,169.90 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 7 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525,090 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 342 | $27.57 | $9,428.94 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 6 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525,967 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 3,205 | $29.20 | $93,586.00 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 5 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,526,309 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 1,582 | $28.56 | $45,181.92 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 4 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,529,514 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 29,624 | $27.48 | $814,067.52 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,531,096 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,220 | $29.15 | $152,163.00 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,560,720 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 14,880 | $28.47 | $423,633.60 |
DisclosureSEC source: 0001658918-26-000010 · form4-05112026_090504.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,565,940 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 15,603 | $29.13 | $454,515.39 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 8 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,580,820 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,098 | $28.04 | $227,067.92 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 7 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,596,423 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 928 | $29.00 | $26,912.00 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 6 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,604,521 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 9,544 | $28.12 | $268,377.28 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 5 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,605,449 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 697 | $30.08 | $20,965.76 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 4 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,614,993 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 311 | $29.56 | $9,193.16 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,615,690 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,427 | $28.37 | $153,963.99 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,616,001 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 9,136 | $27.50 | $251,240.00 |
DisclosureSEC source: 0001658918-26-000008 · form4-05062026_080501.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,621,428 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 7,575 | $27.49 | $208,236.75 |
DisclosureSEC source: 0001658918-26-000006 · form4-04172026_040404.xml · nonDerivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,630,564 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,477 | $27.01 | $66,903.77 |
DisclosureSEC source: 0001658918-26-000006 · form4-04172026_040404.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,638,139 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 9,135 | $26.93 | $246,005.55 |
DisclosureSEC source: 0001658918-26-000006 · form4-04172026_040404.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,640,616 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 93,955 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001658918-26-000004 · form4-02092026_050201.xml · derivative · entry 3 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,955 Underlying: Voting Common Stock · 93,955 shares Expires 2036-02-04 F4 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 23,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001658918-26-000004 · form4-02092026_050201.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,649,751 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | Tax withholdingVoting Common Stock | 204,146 | $17.98 | $3,670,545.08 |
DisclosureSEC source: 0001658918-26-000002 · form4-01292026_040107.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626,606 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | ConversionSeries C Preferred Stock · Derivative | 65,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001658918-25-000008 · form4-10282025_041001.xml · derivative · entry 5 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 3,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | ConversionVoting Common Stock | 3,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001658918-25-000008 · form4-10282025_041001.xml · nonDerivative · entry 2 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 916,164 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001658918-25-000008 · form4-10282025_041001.xml · derivative · entry 4 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 916,164 Underlying: Voting Common Stock · 916,164 shares Expires 2035-10-26 F5 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 225,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001658918-25-000008 · form4-10282025_041001.xml · nonDerivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,693 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| May 10, 2018 Filed Dec 12, 2018 00:43 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 47,666 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-18-062120 · doc4.xml · derivative · entry 1 Kroeger Christopher A. · CIK 0001658918 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,666 Underlying: Common Stock · 47,666 shares Expires 2028-05-10 F1 · derivative.exercise_price: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F1 · shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F2 · derivative.exercise_date: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause). F1 · derivative.underlying_shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F1 · balance_after: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.